Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States

3Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Acute respiratory infections (ARIs) are commonly treated with antibiotics in outpatient settings, but many infections are caused by viruses and antibiotic treatment is therefore inappropriate. FebriDx®, a rapid point-of-care test that can differentiate viral from bacterial infections, can inform antibiotic treatment decisions. Objectives: The primary aim of this study is to conduct a literature-based US economic evaluation of a novel rapid point-of-care test, FebriDx®, that simultaneously measures two key infection biomarkers, C-reactive protein (CRP) and Myxovirus resistance protein A (MxA), to accurately differentiate viral from bacterial infection. Methods: A budget impact model was developed based on a review of published literature on antibiotic prescribing for ARIs in the United States. The model considers the cost of antibiotic treatment, antibiotic resistant infections, antibiotic-related adverse events, and point-of-care testing. These costs were extrapolated to estimate savings on a national level. Results: The expected national cost to treat ARIs under standard of care was US$8.25 billion, whereas the expected national cost of FebriDx point-of-care-guided ARI treatment was US$5.74 billion. Therefore, the expected national savings associated with FebriDx® rapid point-of-care testing was US$2.51 billion annually. Conclusions: FebriDx, a point of care test that can reliably aid in the differentiation of viral and bacterial infections, can reduce antibiotic misuse and, therefore, antibiotic resistant infections. This results in significant cost savings, driven primarily by the reduction in antibiotic resistant infections.

References Powered by Scopus

Community-acquired pneumonia requiring hospitalization among U.S. adults

1826Citations
N/AReaders
Get full text

Prevalence of inappropriate antibiotic prescriptions among us ambulatory care visits, 2010-2011

1348Citations
N/AReaders
Get full text

Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?

1092Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting

16Citations
N/AReaders
Get full text

Use of the FebriDx<sup>®</sup>host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: A mixed-methods feasibility study

1Citations
N/AReaders
Get full text

Towards improved point-of-care (POC) testing for patients with suspected sepsis: POC tests for host biomarkers and possible microbial pathogens

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dick, K., & Schneider, J. (2021). Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States. Journal of Health Economics and Outcomes Research, 8(2), 56–62. https://doi.org/10.36469/jheor.2021.27753

Readers over time

‘21‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

40%

Researcher 2

40%

Lecturer / Post doc 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

43%

Immunology and Microbiology 2

29%

Nursing and Health Professions 1

14%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Article Metrics

Tooltip
Mentions
News Mentions: 11

Save time finding and organizing research with Mendeley

Sign up for free
0